Norway Grapples with Prioritizing Costly Rare Disease Treatments

Oslo, Norway – February 20, 2026 – Norway’s public health service faces increasing challenges in balancing access to innovative, high-cost treatments for rare diseases with the necessitate for sustainable and equitable resource allocation. A recent thesis has shed light on the complexities of this issue, offering insights that could shape future health policy and priority-setting processes.

The Rising Cost of Rare Disease Therapies

New medical advancements are leading to the development of treatments for an increasing number of severe and rare diseases, often accompanied by substantial price tags. This presents a significant dilemma for healthcare systems worldwide and Norway is no exception. The core of the issue lies in determining how to prioritize these expensive therapies within a system of limited resources.

National Policy and the ‘Nye Metoder’ System

Research conducted in 2022 examined the challenges at both a national policy level and within the interactions between physicians and patients. A key development in Norway’s approach to healthcare resource allocation was the establishment of the Decision Forum and the National System for Managed Introduction of New Health Technologies (Nye Metoder). An analysis of media coverage between 2013 and 2019, focusing on debates surrounding high-cost cancer and rare disease treatments, revealed that discussions about individual treatments became less politically charged after the implementation of Nye Metoder [1]. This suggests a move towards a more formalized and less partisan decision-making process.

Public Priorities in Healthcare Allocation

The thesis similarly investigated public perceptions of healthcare prioritization. Findings indicate that the public tends to prioritize patients who are expected to experience reduced informal caregiving needs or improved ability to work – factors considered societal benefits. Patients who could gain more quality-adjusted life years or who have more severe conditions – health-related criteria – were also prioritized, though to a lesser extent. Interestingly, opinions on work ability were influenced by respondents’ own employment status [1].

Physician Perspectives and Clinical Practice

Interviews with 18 physicians regarding the introduction of a new, high-cost treatment for cystic fibrosis in 2022 revealed that physicians often navigate complex situations when translating overarching priority-setting principles into clinical practice. The research highlighted two key findings: physicians negotiate the content of clinical guidelines in their interactions with patients, and they interpret treatment costs in ways that allow them to continue offering therapy, even when the effect is uncertain, rather than discontinuing it [1].

The Importance of International Collaboration

Given Norway’s relatively small population, international cooperation is crucial for providing up-to-date and effective treatments for rare diagnoses [2]. Collaboration is needed across diagnostics, treatment, research, and innovation. A recent study on Cushing’s disease in Western Norway Regional Health Authority, for example, reported an annual incidence of 3.0 per million in the period 2010–22, a figure higher than previously reported, highlighting the challenges of research in rare conditions [2].

Looking Ahead: Transparency and Evidence-Based Guidelines

The research underscores the need for greater transparency in price agreements and clearer, evidence-based criteria in clinical guidelines for high-cost medicines. These improvements can better support clinicians in navigating uncertain treatment effects and contribute to fairer and more transparent priority-setting within the Norwegian health service [1]. Norway’s National Strategy for Rare Diagnoses, established in 2021, also aims to address these challenges by focusing on disease-specific European Reference Networks (ERNs) [3].